NEW YORK (TheStreet) -- Genetic Technologies
(GENE) shares are up 13.2% to $1.16 on Monday after the company announced that the number of BREVAGen breast cancer risk test samples it received this quarter was up 37% over the previous quarter.
The company more than doubled the number of samples it received -- 3,935 compared to 1,547 -- for the fiscal year ending June 30 than it did the previous fiscal year.
The test is a cheek swab was introduced in the U.S. in 2012 that upon completion is sent to Genetic Technologies for analysis.
Must Read: Warren Buffett's 25 Favorite Stocks